Very late-phase vascular response after everolimus-eluting stent implantation assessed by optical coherence tomography.
Aged
Aged, 80 and over
Atherectomy, Coronary
Cardiovascular Agents
/ administration & dosage
Coronary Artery Disease
/ diagnostic imaging
Coronary Vessels
/ diagnostic imaging
Drug-Eluting Stents
Everolimus
/ administration & dosage
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Predictive Value of Tests
Prosthesis Design
Registries
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Everolimus-eluting stent
First generation drug-eluting stent
Late vascular response
Optical coherence tomography
Stent malapposition
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
18
01
2020
accepted:
02
05
2020
pubmed:
10
5
2020
medline:
6
10
2020
entrez:
10
5
2020
Statut:
ppublish
Résumé
Long-term safety of second generation drug-eluting stents (DES) has not yet been evaluated. We sought to evaluate the very late phase (> 3 years) vascular response after second generation everolimus-eluting stent (EES) as compared with first generation sirolimus-eluting stent (SES) by using optical coherence tomography (OCT). We examined the vascular response in 39 patients with a total of 55 DESs [31 EESs (mean 54 months after stenting) and 24 first generation SES (mean 66 months after stenting)] by OCT. The frequency of lesions with any malapposed stent struts (19% vs. 46%, p = 0.035) and evagination (6% vs. 42%, p = 0.002) was significantly lower. Segments with malapposed stent struts were significantly shorter (0.4 ± 0.9 mm vs. 1.9 ± 3.5 mm, p = 0.024), maximal malapposition area and malapposition volume were significantly smaller (0.26 ± 0.38 mm
Identifiants
pubmed: 32385540
doi: 10.1007/s10554-020-01877-7
pii: 10.1007/s10554-020-01877-7
doi:
Substances chimiques
Cardiovascular Agents
0
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM